Viridian Therapeutics, Inc. (VRDN) on GreekSoup https://greeksoup.ai/stocks/us/vrdn/ Every dated entry in the public record on Viridian Therapeutics, Inc.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Wed, 28 Oct 2026 00:00:00 +0000 Viridian Therapeutics, Inc.: short interest 18,002,311 shares at the 15 October 2026 settlement, 8.02 days to coverhttps://greeksoup.ai/stocks/us/vrdn/short-interest/us:VRDN:short-interest:2026-10-15:4707755fd7Thu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: short interest 17,965,668 shares at the 30 September 2026 settlement, 8.87 days to coverhttps://greeksoup.ai/stocks/us/vrdn/short-interest/us:VRDN:short-interest:2026-09-30:17f9e1df87Wed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: short interest 19,465,251 shares at the 15 September 2026 settlement, 15.74 days to coverhttps://greeksoup.ai/stocks/us/vrdn/short-interest/us:VRDN:short-interest:2026-09-15:2061cc51c3Tue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: short interest 19,511,841 shares at the 31 August 2026 settlement, 16.55 days to coverhttps://greeksoup.ai/stocks/us/vrdn/short-interest/us:VRDN:short-interest:2026-08-31:7e24cc5d8dMon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: Schedule 13G filed by Point72 Asset Management, L.P., 5.0% of the classhttps://greeksoup.ai/stocks/us/vrdn/holders/us:VRDN:schedule-13:2026-08-20:56d3f507a1Thu, 20 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: Tousignant Jennifer (Chief Legal Officer) sold 4,212 shares at $24.50 on 19 August 2026, $103,194https://greeksoup.ai/stocks/us/vrdn/insiders/us:VRDN:insider:2026-08-20:7f5e77c549Thu, 20 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: Tousignant Jennifer (Chief Legal Officer) sold 10,000 shares at $24.50 on 19 August 2026, $245,000https://greeksoup.ai/stocks/us/vrdn/insiders/us:VRDN:insider:2026-08-20:f1c0f5b524Thu, 20 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: Form 144, Tousignant Jennifer plans to sell 14,212 shares worth $348,194 around 19 August 2026https://greeksoup.ai/stocks/us/vrdn/planned-sales/us:VRDN:planned-sale:2026-08-19:f96476ba17Wed, 19 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: Schedule 13G/A filed by Kynam Capital Management, LP, 5.7% of the classhttps://greeksoup.ai/stocks/us/vrdn/holders/us:VRDN:schedule-13:2026-08-14:dc2226a15cFri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: Schedule 13G/A filed by Deep Track Capital, LP, 3.2% of the classhttps://greeksoup.ai/stocks/us/vrdn/holders/us:VRDN:schedule-13:2026-08-14:45b1369004Fri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: Schedule 13G/A filed by Paradigm BioCapital Advisors LP, 6.1% of the classhttps://greeksoup.ai/stocks/us/vrdn/holders/us:VRDN:schedule-13:2026-08-14:892904bf17Fri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: Schedule 13G filed by T. Rowe Price Associates, Inc., 5.2% of the classhttps://greeksoup.ai/stocks/us/vrdn/holders/us:VRDN:schedule-13:2026-08-14:5b69bfe873Fri, 14 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: short interest 19,026,492 shares at the 14 August 2026 settlement, 9.05 days to coverhttps://greeksoup.ai/stocks/us/vrdn/short-interest/us:VRDN:short-interest:2026-08-14:c967341fd1Fri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: Schedule 13G filed by STATE STREET CORPORATION, 5.5% of the classhttps://greeksoup.ai/stocks/us/vrdn/holders/us:VRDN:schedule-13:2026-08-07:f79f934f65Fri, 07 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc. Q2 FY2026 results: revenue $284,000, net income -$127 millionhttps://greeksoup.ai/stocks/us/vrdn/results/fy2026-q2/us:VRDN:result:2026-08-06:a4ab91c7d3Thu, 06 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/vrdn/filings/us:VRDN:filing:2026-08-06:dd3e743a01Thu, 06 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc. filed 8-K: results of operationshttps://greeksoup.ai/stocks/us/vrdn/filings/us:VRDN:filing:2026-08-06:28c547b9a1Thu, 06 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> Viridian Therapeutics, Inc.: short interest 19,234,874 shares at the 31 July 2026 settlement, 11.31 days to coverhttps://greeksoup.ai/stocks/us/vrdn/short-interest/us:VRDN:short-interest:2026-07-31:529569d84aFri, 31 Jul 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]>